Aktienanalyse zu Mediwound Ltd (MDWD)MDWDMediwound Ltd

Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain. It operates in the Healthcare sector (MEDICINAL CHEMICALS AND BOTANICAL PRODUCTS industry).

MediWound Ltd is a good buy right now due to its recent positive developments in clinical trials and a strong analyst rating. The current price is $13.50, which is significantly below the analyst price target of $27, indicating a potential upside of 100%. Additionally, the stock has shown a 5-day change of +11.89%, suggesting positive momentum. However, investors should be cautious of the company's high net loss of $7.4 million in Q2 2026, which highlights ongoing financial challenges.

5 analysts cover MDWD: 5 rate it Buy, 0 Hold and 0 Sell. The average price target is 30.00.